news
Bluebird Bio bought, relaunched as Genetix, now profitable
David Meek bought distressed gene therapy company Bluebird Bio, turned it into Genetix, and claims the rebranded company is already making money. This signals a potential resurgence for a biotech player previously struggling with commercialization bottlenecks. It's a look at how a change in leadership and strategy can revive a company even in complex fields like gene therapy.
David Meek bought distressed gene therapy company Bluebird Bio, turned it into Genetix, and claims the rebranded company is already making money. This signals a potential resurgence for a biotech player previously struggling with commercialization bottlenecks. It's a look at how a change in leadership and strategy can revive a company even in complex fields like gene therapy.
The architecture take
Call it a rebranding, call it a rescue mission — this is less about the drug pipeline and more about the financial mechanism. A distressed asset got a facelift and a new set of books. Watch for how long those profits hold if product delivery stays slow.